Opendata, web and dolomites

PAPRAT SIGNED

PAPRAT (Predictive Algorithm for Pre-Rheumatoid Arthritis Treatment). The new and most efficient multiple biomarkers-based system for an early selection of RA treatment intensity

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PAPRAT project word cloud

Explore the words cloud of the PAPRAT project. It provides you a very rough idea of what is the project "PAPRAT" about.

algorithm    population    poorly    variables    drivers    finished    genetics    therapy       once    combined    health    demographical    leave    accuracy    service    difficult    optimize    remission    licensing    accurate    treatment    lack    antibodies    17    total    anti    biomarker    protein    multiple    discerning    paprat    launch    arthritis    needing    genetic    efficient    grow    administration    epigenetic    validate    joints    prognosis    biological    outcome       patients    82    dmards    suffering    disease    good    critical    biosimilars    unclassified    deformity    market    software    world    bone    delays    acpa    unnecessary    classifying    medium    classify    degenerative    medicine    globally    combines    rf    deterioration    aggressive    calculate    prognostics    reduce    disability    bn    pain    proper    ra    complications    yearly    trl6    citrullinated    platform    burden    start    prepare    40    spanish    few    spent    rheumatoid    45    ageing    blood    organs    index    continued    personalized    genomic    markers    clinical    predictive    economic    designed    complete    severity    3m    addressable   

Project "PAPRAT" data sheet

The following table provides information about the project.

Coordinator
MAKING GENETICS S.L. 

Organization address
address: PLAZA CEIN 1, POLIGONO MOCHOLI, OFICINA R1.9, NOAIN
city: NOAIN
postcode: 31110
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-09-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MAKING GENETICS S.L. ES (NOAIN) coordinator 50˙000.00

Map

 Project objective

Rheumatoid arthritis (RA) affects 1% of world population (17.6 M) and it is a relevant economic burden (€45 Bn spent yearly in Europe). It is a degenerative disease that affects bone health, cause joints’ deformity, impact other organs and cause disability. An early and personalized treatment can greatly improve its outcome, achieve remission and reduce pain, thus an accurate prognosis is critical for its efficient management. However, this is difficult for the lack of good prognosis factors (currently rheumatoid factor-RF or anti-citrullinated protein antibodies-ACPA), which at present are very few, poorly accurate and leave 40% of patients unclassified (suffering health complications due to an unnecessary aggressive treatment or from deterioration due to delays in proper treatment). Making Genetics is a Spanish start-up focused in personalized medicine through genomic approaches. We have designed and developed a prognostics test for RA based on a blood test and the use of our new PAPRAT algorithm, with 82.4% accuracy. PAPRAT is a multiple biomarker-based system capable of classifying pre-rheumatoid arthritis patients, discerning which will need a more aggressive treatment. It combines unique genomic markers (genetic and epigenetic), as well as clinical and demographical variables, to calculate a predictive index and classify patients’ RA severity as HIGH (needing early administration of a combined therapy with biological DMARDs) or LOW and MEDIUM (non-biological DMARDs are enough). It is at a TRL6 and now we aim to optimize it, further validate it, develop a software platform and prepare its market launch. RA is expected to grow by drivers such as an ageing population or the continued uptake of biosimilars, and we have currently a total addressable market of 17.6 M patients globally and of around 3M in Europe. We will offer a complete prognosis service, including the blood testing, as well as the licensing of our software platform once it is finished.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PAPRAT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PAPRAT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DNA DS (2019)

DNA Data storage

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More